by Dan Roberts November 2009 A 2009 study* has shown that implantation of a blue light-filtering intraocular lens (IOL) at the time of cataract surgery increases macular pigment in the retina. This increase may provide protection against the development and/or progression of AMD. The study was reported by the Macular Pigment Research Group at the [Read More]
News
Brachytherapy May Reduce Burden of Treatment and Further Improve Visual Acuity
(Updated August 26, 2020) San Francisco, CA (PRWEB) October 27, 2009 — NeoVista, Inc. made public at the American Academy of Ophthalmology meeting the company’s interim study results from the preliminary study MERITAGE-I. The study was designed to examine the company’s novel epimacular brachytherapy procedure when used in patients that require chronic anti-VEGF treatment for [Read More]
Driving Safely
by Edward J. Huggett, O.D. (Originally published August 2009) I am often asked, “How long is it safe to drive when your vision is deteriorating?” There are three visual factors that are important to consider when it comes to driving. Visual acuity (VA), visual field (VF) and contrast sensitivity (CS). There are others I will [Read More]
Lipschitz Macular Implant Allows Bilateral Magnification of Vision
On June 17, 2009, OptoLight Vision Technology announced that it received a CE mark for its Lipshitz Macular Implant (LMI), named for its inventor, Isaac Lipshitz. This will allow OptoLight to immediately begin marketing the implant in Europe and other markets outside of the United States. On December 28, 2007, Optolight Vision Technology announced success [Read More]
siRNA Turns Off Bad Genes
by Dan Roberts (updated April 2009) A new type of anti-VEGF drug called “small interference RNA (siRNA),” is showing promise in its ability to turn off genes that cause wet AMD. A preliminary primate study in early 2004 showed that, at the highest dose used in the study siRNA (formerly called RNAi) “reduced the incidence [Read More]